Acurable, a U.K.-based medical device company, announced it raised €11 million ($10.8 million) in a Series A funding round led by Kibo Ventures. Mundi Ventures, Comprador Holdings and Kindred Capital participated in the raise.
The company will use the funds to accelerate the international expansion of its first home sleep-testing device, the AcuPebble SA100, which enables users to detect and...
Pfizer completes ResApp purchase for over $115 million
Biopharmaceutical giant Pfizer has finalised its acquisition of ASX-listed digital health startup ResApp for A$179 million ($116 million), according to the University of Queensland.
Brisbane-based ResApp has developed a mobile app that analyses cough sounds and diagnoses respiratory diseases, including asthma, pneumonia, bronchiolitis, croup...
harrison.ai, Sonic Healthcare launch pathology AI joint venture
Healthcare AI startup harrison.ai and ASX-listed diagnostics provider Sonic Healthcare have set up a joint venture namedfranklin.ai.
Based on a media release, franklin.ai will develop and provide pathologists with AI-powered support tools to improve diagnosis accuracy and efficiency.
The venture will be led by harrison.ai's former...
ASX-listed ResApp Health has received the US Food and Drug Administration's 510(k) clearance for SleepCheckRx, its mobile sleep apnoea screening app.
Introduced two years ago, SleepCheck is an at-home test for adults who are at risk of moderate to severe obstructive sleep apnoea. It screens for the condition by analysing breathing and snore sounds recorded via phone.
It has been approved as a...
Biopharmaceutical giant Pfizer has offered AU$100 million (US$74.43 million) to acquire Australian company ResApp, which has developed a mobile app to diagnose COVID-19 by the sound of a person's cough.
In its announcement of the proposed acquisition to the Australian Stock Exchange, ResApp said Pfizer will acquire 100 per cent of the company's shares following an anticipated positive shareholder...
ASX-listed digital health firm ResApp Health has announced that its pilot clinical trial for a smartphone-based COVID-19 screening test has achieved positive results.
The new diagnostic app, which uses machine learning to analyse the sound of a patient's cough, was reported to correctly detect COVID-19 in 92% of participants with the infection during the trial. With a 92% sensitivity, it exceeds...
ASX-listed ResApp Health has inked a two-year deal with Health Teams, a digital aged care platform, to launch its mobile diagnostic app on the latter's telehealth platform.
ResAppDx is an app-based acute respiratory diagnostic test that uses machine learning to analyse cough sounds and diagnose respiratory diseases. Approved for use in Australia and Europe, the app can be integrated with...
Brisbane-based digital health company, ResApp Health has announced the launch of SleepCheck, a mobile medical device software application that analyses a user’s breathing and snoring sounds during sleep and provides an assessment of their risk of sleep apnoea.
The app uses the smartphone’s built-in microphone to record the user’s breathing and snoring sounds while they sleep. SleepCheck’s...
Brisbane-based ResApp, which creates smartphone apps for the diagnosis and management of respiratory diseases, last week announced its plans to launch SleepCheck, an at-home obstructive sleep apnoea (OSA) screening app. The company said it plans to launch SleepCheck for iOS on the App Store in the United Kingdom and Australia in the second quarter of this calendar year, with availability in...
Brisbane, Australia-based public company ResApp, which creates smartphone apps for the diagnosis and management of respiratory diseases, announced last week that it has received firm commitments from institutional and sophisticated investors to raise $5 million.
The funds raised will be used to accelerate European commercialization and for general working capital. The placement received strong...
